Astellas Pharma Inc. and Medivation, Inc. have announced that the Independent Data Monitoring Committee (IDMC) has informed the companies of positive results from a planned interim analysis of the Phase 3 PREVAIL trial of XTANDI (enzalutamide) in more than 1,700 men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed despite androgen deprivation therapy and who have not received chemotherapy[i]...
No comments:
Post a Comment